Anuh Pharma Limited · NSE:ANUHPHR
Anuh Pharma — Q1 FY27 Earnings Presentation
30 slides from Anuh Pharma's earnings presentation, August 2026
Slide 1: Anuh Pharma Ltd. Investor Presentation Q1 FY27
ANUH PHARMA LTD. Investor Presentation Q1 FY27 | August 2026 BSE - 506260, NSE- ANUHPHR Bloomberg: ANUH IN | Reuters: ANUH.BO www.anuhpharma.com 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement ▪ This presentation may include certain "forward looking statements", based on current expectations, within the meaning of applicable laws and regulations. ▪ Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaim
Slide 3: Table of Contents
01 Q1 FY27 & FY26 Performance 02 Company Overview Table of Contents 03 Infrastructure 04 Future Outlook 05 Corporate Social Responsibility 3
Slide 4: Q1 FY27 & FY26 Performance
01 Q1 FY27 & FY26 Performance 4
Slide 5: Q1 FY27 at a Glance
Q1 FY27 at a Glance Rs. in Crores Operating Revenue Operating Profit EBITDA Profit Before Tax 193.81 38.15 19.36 16.93 +3.93% YoY +39.50% YoY +41.56% YoY +54.55% YoY Rs. 186.48 Cr in Q1 FY26 19.68% margin 9.99% margin vs 7.34% LY 8.74% margin vs 5.87% LY PAT ROCE EPS (Rs.) Production (MT) 11.42 19.1
Slide 6: Message from the Joint Managing Directors – Q1 FY27
Message from the Joint Managing Directors – Q1 FY27 Q1 FY27 – PROFITABILITY Dear Shareholders, Investors and Partners, FY27 has opened on a confident note, with profit growth running Revenue (Cr) 193.81 +3.93% well ahead of revenue - a deliberate outcome of our shift towards higher-value products in
Slide 7: Q1 FY27 Financial Performance
Q1 FY27 Financial Performance Rs. in Crores Financial Highlights Q1 FY27 Q4 FY26 % QoQ Q1 FY26 % YoY Operating Revenue 193.81 202.12 (4.11) 186.48 3.93 Operating Profit * 38.15 44.44 (14.15) 27.35 39.50 % of Margin 19.68 21.99 14.66 Other Income 3.08 (1.25) (345.23) 3.39 (9.20) EBITDA 19.36 18.63 3.
Slide 8: Five-Year Financial Track Record
Five-Year Financial Track Record Rs. in Crores | FY22 - FY26 Total Revenue EBITDA 87.2 776.0 659.0 671.0 70.4 66.1 537.0 52.0 57.4 491.8 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Profit Before Tax and Profit After Tax PBT PAT 78.3 60.1 61.0 54.2 39.1 47.5 47.4 47.4 30.6 36.2 FY22 FY23 FY24 F
Slide 9: Balance Sheet Strength & Shareholder Returns
Balance Sheet Strength & Shareholder Returns FY22 - FY26 Dividend Outflow (Rs. Cr.) Current Ratio (x) 2.20 2.22 15.03 15.03 12.53 2.11 8.77 10.02 1.98 1.91 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Debt to Equity (x) Cash Conversion Cycle (Days) 0.03 86 72 58 56 61 0.01 0.01 0.00 0.00 FY22 F
Slide 10: Revenue Mix & Customer Concentration
Revenue Mix & Customer Concentration Q1 FY27 vs Q1 FY26 Domestic vs Export Revenue (Rs. Cr.) Top 5 Customers - Share of Sales Domestic Export Q1 FY27 Q1 FY26 194 186 55% 70 88 37% 36% 34% 30% 20% 124 98 Q1 FY27 Q1 FY26 Export Domestic Total 10
Slide 11: Export Revenue by Geography
Export Revenue by Geography % of export sales Q1 FY27 Q1 FY26 2.6% 3.1% 26.8% 27.9% 35.7% 30.9% 4.2% 3.8% 35.5% 29.6% Asia Europe North America Asia Europe North America Africa Latin America Africa Latin America 11
Slide 12: Product Mix - Q1 FY27 vs Q1 FY26
Product Mix - Q1 FY27 vs Q1 FY26 Rs. in Crores Revenue by Product Group Q1 FY27 Q1 FY26 Erythromycin 49.1 63.6 Higher Macrolides 39.9 19.7 Sulphadoxine 37.0 11.0 Cortico Steroids 20.1 20.9 Pyrazinamide 12.2 10.3 Gliclazide 11.9 5.1 Other Items 10.9 34.7 Ambroxol HCL 7.9 8.4 Chloramphenicol 4.0 12.2
Slide 13: Company Overview
02 Company Overview 13
Slide 14: Anuh Pharma at a Glance
Anuh Pharma at a Glance API manufacturer since 1989 ~46% 360 72+ 2 of FY26 revenue from marketing partners / countries served facilities - Tarapur & exports customers Mahape Business Profile Infrastructure & Group ▪ One of the largest manufacturers of Macrolides and ▪ Manufacturing facility at Tarap
Slide 15: Journey So Far
Journey So Far 1989 - 2026 FOUNDATION 1989 - 2010 GLOBAL APPROVALS 2012 - 2019 SCALE & GROWTH 2020 - 2026 1989 Started manufacturing 2012 Acquired R&D assets of Invent 2020 WHO Geneva pre-qualification Erythromycin salts with capacity of 150 Pharma (Spain); DSIR approval. for Pyrimethamine API. MTPA
Slide 16: Competitive Advantage
Competitive Advantage Market Leadership Why Customers Choose Anuh Products where Anuh holds a leading position Regulatory approvals Erythromycin salts USFDA, EU GMP, WHO-GMP, EDQM CEPs and WHO Geneva pre- qualifications across the portfolio. Environmental, health and safety compliance Pyrazinamide A
Slide 17: Product Portfolio
Product Portfolio 12 therapeutic categories MACROLIDES Erythromycin 11,12 Carbonate · Erythromycin Base · Erythromycin Estolate · Erythromycin Propionate · Erythromycin Ethyl Succinate · Erythromycin Phosphate · Erythromycin Stearate CORTICOSTEROIDS Beclomethasone Dipropionate · Betamethasone Acetat
Slide 18: Board & Senior Management
Board & Senior Management Board of Directors Senior Management Mr. Arun Todarwal / Chairman Mr. Raju Kotadia / CMO - EM Fellow member of the ICAI, in practice since 1981. Has been BSc Chemistry; part of Anuh Pharma since inception, a director of several large listed corporations in India, handling o
Slide 19: Shareholding Pattern
Shareholding Pattern As on 10th August 2026 Ownership Structure Promoter & Promoter Group 71.80% Public 28.20% 28.20% Market Capitalisation 71.80% INR 779 Cr. Free Float Market Cap. Promoter & Promoter Group Public INR 220 Cr. 19
Slide 20: Infrastructure
03 | iy | | Infrastructure
Slide 21: State of the Art Manufacturing Facility
State of the Art Manufacturing Facility Tarapur, Maharashtra 11,400 9 2 2,400 sq. meters site area API blocks intermediate blocks MTPA total capacity USD FDA / EU GMP / WHO Pre-qualified Site Other Facilities Anuh Pharma has an US FDA, EU GMP, WHO pre- ▪ Zero Liquid Discharge effluent control system
Slide 22: Inside the Tarapur Facility
Inside the Tarapur Facility 9 API blocks | 2 intermediate blocks 22
Slide 23: Manufacturing Facility
Manufacturing Facility Tarapur, Maharashtra | 11,400 sq. m site Aerial view of the Tarapur manufacturing complex - 9 API blocks and 2 intermediate blocks.
Slide 24: Inside the Plant
Inside the Plant EU GMP / WHO pre-qualified operations Clean-room corridors, reactor halls and finished-goods warehousing at Tarapur.
Slide 25: Dedicated Research & Development Facility
Dedicated Research & Development Facility Mahape, Navi Mumbai 10,000 DSIR 2012 sq. ft. R&D facility at Mahape approved R&D centre acquired R&D assets of Invent Pharma, Spain ANALYTICAL DEVELOPMENT CHEMICAL SYNTHESIS PILOT PLANT Facilitate activities that lead to Develop processes and products. Lab s
Slide 26: Future Outlook
04 Future Outlook 26
Slide 27: Future Outlook - Growth Strategy
Future Outlook - Growth Strategy Growth Levers Products Under Development ▪ Extensive volume expansions across our API lines, coupled with high- value regulated market growth. 01 Vonoprazon Fumarate Anti-Ulcerative ▪ Continued priority on process innovation and cost optimisation. ▪ Strategic market
Slide 28: Corporate Social Responsibility
05 Corporate Social Responsibility 28
Slide 29: Corporate Social Responsibility
Corporate Social Responsibility Servicing society for a better tomorrow Chhatrapati Shikshan Mandal Indian Development Foundation Churchgate Lions Service Funds Building of a toilet block for about Project Aashayein - education for Promoting sports for specially 3,200 students of the school. underpr
Slide 30: Thank You
Thank You For specific queries, please feel free to contact: Anuh Pharma Ltd. Mr. Darshan Rampariya www.anuhpharma.com BSE: 506260, NSE: ANUHPHR Chief Financial Officer darshan.r@anuhpharma.com 30